News | July 06, 2024
Biogen completes acquisition of HI-Bio
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
Dyslipidemia is a critical risk factor for cardiovascular diseases
The initiative aimed to reach and support individuals suffering from epilepsy through early detection and effective disease management
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Ibara will drive AI-powered clinical research innovation
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Imfinzi also recommended for patients with mismatch repair deficient disease
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Doxycycline capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients
Subscribe To Our Newsletter & Stay Updated
